Handelsbanken Fonder Ab Novo Cure LTD Transaction History
Handelsbanken Fonder Ab
- $26.2 Billion
- Q4 2024
A detailed history of Handelsbanken Fonder Ab transactions in Novo Cure LTD stock. As of the latest transaction made, Handelsbanken Fonder Ab holds 37,523 shares of NVCR stock, worth $827,382. This represents 0.0% of its overall portfolio holdings.
Number of Shares
37,523
Previous 34,223
9.64%
Holding current value
$827,382
Previous $535,000
108.97%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding NVCR
# of Institutions
288Shares Held
75.6MCall Options Held
1.77MPut Options Held
538K-
Black Rock Inc. New York, NY12.1MShares$268 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$260 Million0.01% of portfolio
-
Capital International Investors Los Angeles, CA8.87MShares$196 Million0.05% of portfolio
-
Capital World Investors Los Angeles, CA4.82MShares$106 Million0.02% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.74MShares$60.4 Million5.68% of portfolio
About NovoCure Ltd
- Ticker NVCR
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 104,950,000
- Market Cap $2.31B
- Description
- NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...